Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07127757

Clinical Evaluation of WaveLight Plus LASIK

This study is a single-site, single-arm, prospective, observational study of subject satisfaction, quality of vision, and quality of life after bilateral LASIK surgery. Subjects will be assessed up to 3 months post-operatively. Clinical evaluations will include refractive outcomes, visual acuity, and administration of the adapted PROWL and Low Luminance Questionnaire (LLQ-32) Questionnaire.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Laser Defined Vision

Greensboro, North Carolina, 27401, United States

Location status: Recruiting

Location contact

Carrie Willams

CONTACT

[email protected]

336-288-8823

Karl Stonecipher, MD

PRINCIPAL_INVESTIGATOR

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject must be able to understand and sign an IRB approved Informed consent form
  • Willing and able to attend all scheduled study visits as required per protocol
  • Minimum of 18 years of age
  • Myopia up to -8.00 D, astigmatism up to -3.00 D, with SE more than -1.00D and up to -9.00D, based on Sightmap measured refraction
  • Best corrected photopic distance visual acuity of 20/20-2 or better (≤ 0.04 logMAR)
  • Mesopic pupil size ≥ 4.5mm
  • Less than 0.75 D manifest refraction spherical equivalent difference between Sightmap refraction and subjective manifest refraction
  • Stable refraction (within ± 0.50 D) as determined by manifest refraction spherical equivalent for a minimum of 12 months prior to surgery, verified by consecutive subjective refractions or medical records or prescription history
  • If currently wearing contact lenses:
  • Soft CTL wearers discontinue for minimum 3 days prior to first refraction
  • RGP or toric soft CTL wearers discontinue for ≥2 weeks prior to first refraction

Exclusion criteria

  • Subjects who are pregnant or nursing
  • Acute or chronic disease or illness that would increase the operative risk or confound the outcomes of the study
  • Patients with flap complications
  • Systemic medications that may confound the outcome of the study or increase the risk to the subject.
  • Ocular condition (other than high myopia) that may predispose the subject to future complications, such as ectasia
  • History or evidence of active or inactive corneal disease (e.g., herpes simplex keratitis, herpes zoster keratitis, recurrent corneal erosion syndrome, corneal dystrophy)
  • Evidence of retinal vascular disease
  • Keratoconus or Keratoconus suspect
  • Glaucoma or glaucoma suspect by exam findings and/or family history
  • Previous intraocular or corneal surgery
  • Predicted residual stromal bed thickness < 250 μm
  • Intended to have monovision treatment
  • Participation in other current clinical trials

Treatment and study plan

Wavelight Plus LASIK

Device

Wavelight plus LASIK is an advanced laser eye surgery technology designed to enhance visual outcomes through personalized treatment plans. This system integrates comprehensive diagnostics, including biometry, tomography, and wavefront measurements, to create a tailored ablation profile for each patient.

Primary outcomes

  1. % of eyes with UDVA of 20/10, 20/12.5, 20/16 and 20/20 in photopic conditions at 3 months (monocular and binocular)

    Time frame: 3 months postoperatively

  2. % of eyes with UDVA of 20/10, 20/12.5, 20/16 and 20/20 in mesopic conditions at 3 months (monocular and binocular)

    Time frame: 3 months postoperatively

  3. % of eyes with CDVA of 20/10, 20/12.5, 20/16 and 20/20 in photopic conditions at 3 months (monocular and binocular)

    Time frame: 3 months postoperatively

Secondary outcomes

  1. % of eyes that achieve UDVA equal to or better than preoperative CDVA

    Time frame: 3 months postoperatively

  2. % of eyes with lines gained/lost lines (post-up UDVA VS pre-op CDVA)

    Time frame: 3 months postoperatively

  3. % of eyes with absolute MRSE within +/- 0.25, 0.50, 0.75, and 1.00D at 3 months

    Time frame: 3 months postoperatively

  4. % of eyes that achieved manifest refraction cylinder within +/- 0.25, 0.50, 0.75, and 1.00D at 3 months

    Time frame: 3 months postoperatively

  5. Patient-Reported Outcomes with the modified PROWL Questionnaire and Low Luminance Questionnaire (LLQ-32) at 3 months

    Time frame: 3 months postoperatively

Other outcomes

  1. % of eyes with 10% contrast UDVA (mesopic, binocular) of 20/10, 20/12.5, 20/16, 20/20 and 20/25 at 3 months

    Time frame: 3 months postoperatively

  2. % of eyes with 10% contrast CDVA (mesopic, binocular) of 20/10, 20/12.5, 20/16, 20/20 and 20/25 at baseline and 3 months

    Time frame: 3 months postoperatively

  3. % of eyes with UDVA of 20/8 in photopic conditions at 3 months (monocular and binocular)

    Time frame: 3 months postoperatively

  4. % of eyes with CDVA of 20/8 in photopic conditions at 3 months (monocular and binocular)

    Time frame: 3 months postoperatively

Study contacts

Contact information is provided by the study sponsor or research team.

Carrie Williams

CONTACT

[email protected]

336-288-8823

Sponsors and collaborators

Lead sponsor

Laser Defined Vision

Other

Collaborators

  • Sengi

Registry information

Official study title

Clinical Evaluation of Visual Outcomes With the Wavelight Plus Excimer Laser in Normal and Dim Lighting

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Aug 17, 2025
Registry last updated
Oct 2, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.